Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus
2022; Massachusetts Medical Society; Volume: 387; Issue: 10 Linguagem: Inglês
10.1056/nejmoa2118025
ISSN1533-4406
AutoresRichard Furie, Ronald van Vollenhoven, Kenneth Kalunian, Sandra Navarra, Juanita Romero‐Díaz, Victoria P. Werth, Xiaobi Huang, George Clark, Hua Carroll, Adam Meyers, Cristina Musselli, Catherine Barbey, Nathalie Franchimont,
Tópico(s)T-cell and B-cell Immunology
ResumoAntibody-binding of blood dendritic cell antigen 2 (BDCA2), which is expressed exclusively on plasmacytoid dendritic cells, suppresses the production of type I interferon that is involved in the pathogenesis of systemic lupus erythematosus (SLE). The safety and efficacy of subcutaneous litifilimab, a humanized monoclonal antibody that binds to BDCA2, in patients with SLE have not been extensively studied.
Referência(s)